ReviewBiomarker research2026
Genetic orchestration of the primary central nervous system lymphoma microenvironment.
Review in Biomarker research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Primary central nervous system lymphoma (PCNSL) of the CNS is a distinct entity of diffuse large B-cell lymphoma (DLBCL). CNS lymphomas primarily occur in immune-privileged sites and tend to be confined to extranodal locations such as the brain, spinal cord, meninges, and/or eyes. Due to the presence of the blood-brain barrier and the inherent "immune privilege" characteristics of brain tissue, the tumor microenvironment (TME) of PCNSL exhibits unique features. Additionally, genetic factors originating from the lymphoma cells themselves significantly influence the TME. Substantial evidence has demonstrated that PCNSL exhibits highly characteristic molecular genetic alterations, with a mutational profile distinctly different from that of systemic DLBCL. These unique genetic variations collectively shape the malignant biological behavior of PCNSL, including activation of signal transduction, evasion of immune surveillance, and promotion of malignant progression. Here, we synthesize current evidence to conceptualize the genetic-TME axis as a unifying framework for PCNSL biology, wherein tumor-intrinsic genetic alterations and the specialized CNS microenvironment interact bidirectionally to shape immune evasion, tumor evolution, and therapeutic response. We review the distinctive genetic landscape of PCNSL, the cellular and molecular architecture of its TME, and the reciprocal mechanisms linking these compartments during disease progression. Integrating these dimensions may refine molecular stratification, facilitate biomarker-guided therapeutic selection, and inform more rational treatment strategies for PCNSL.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.